SCHEMBL6359182

SCHEMBL6359182

COCC(=O)N(CC(=O)c1ccccc1)C(C(=O)O)C(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.39
NPC1 O15118 3/20 0.38
MEN1 O00255 2/20 0.38
L3MBTL1 Q9Y468 4/20 0.38
ALDH1A1 P00352 4/20 0.38
POLB P06746 3/20 0.38
LMNA P02545 3/20 0.38
HSD17B10 Q99714 1/20 0.38
TSHR P16473 2/20 0.37
KDM4E B2RXH2 3/20 0.37
USP2 O75604 1/20 0.37
HTT P42858 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
MAPT P10636 4/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
RAB9A P51151 2/20 0.36
AGTR1 P30556 3/20 0.35
ABCB11 O95342 1/20 0.35
GP6 Q9HCN6 1/20 0.35
LTB4R2 Q9NPC1 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6347935 1.00 KMT2A (0.39) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6359360 0.90 KMT2A (0.38) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6350685 0.90 KMT2A (0.38) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6350485 0.83 KMT2A (0.44) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6350978 0.81 ALDH1A1 (0.45) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6359362 0.81 TSHR (0.42) KMT2AMEN1L3MBTL1ALDH1A1POLB
SCHEMBL6358298 0.81 TSHR (0.42) KMT2AMEN1L3MBTL1ALDH1A1POLB
SCHEMBL6349361 0.81 ALDH1A1 (0.45) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6356051 0.81 ALDH1A1 (0.45) KMT2ANPC1MEN1L3MBTL1ALDH1A1
SCHEMBL6352412 0.81 KMT2A (0.43) KMT2AMEN1L3MBTL1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 KMT2A 3612/4885NPC1 2985/4885MEN1 3756/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.